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Prug-Eluting Stents in the
reatment of Intermediate Lesions
ooled Analysis From Four Randomized Trials
effrey W. Moses, MD, FACC,* Gregg W. Stone, MD, FACC,* Eugenia Nikolsky, MD, PHD, FACC,*
ary S. Mintz, MD, FACC,* George Dangas, MD, PHD, FACC,* Eberhard Grube, MD,†
tephen G. Ellis, MD, FACC,‡ Alexandra J. Lansky, MD, FACC,* Giora Weisz, MD,*
artin Fahy, MSC,* Yingbo Na, MSC,* Mary E. Russell, MD, FACC,§ Dennis Donohoe, MD,
artin B. Leon, MD, FACC,* Roxana Mehran, MD, FACC*
ew York, New York; Siegburg, Germany; Cleveland, Ohio; Natick, Massachusetts; and Warren, New Jersey
OBJECTIVES To address the safety and efficacy of drug-eluting stents (DES) in the treatment of
intermediate lesions, we performed a pooled analysis of four randomized DES versus
bare-metal stent (BMS) trials and assessed outcomes among patients with intermediate
lesions.
BACKGROUND Before the introduction of DES, intermediate coronary lesions were commonly managed
based on physiologic or anatomic assessment of lesion severity. The DES may challenge this
paradigm.
METHODS The study population involved 167 of 2,478 randomized patients (6.7%) with intermediate
lesions (diameter stenosis 50% [mean 44%] by quantitative coronary angiography) from the
Sirolimus-coated Bx Velocity Balloon Expandable Stent in the Treatment of Patients with
De Novo Coronary Artery Lesions (SIRIUS), TAXUS-IV, and the First and Second First
Use to Underscore Restenosis Reduction with Everolimus (FUTURE-I and -II) trials. End
points examined included early (in-hospital and 30-day) and late (1-year) major adverse
cardiac events (MACE), including cardiac death, myocardial infarction (MI), target vessel
revascularization (TVR), stent thrombosis, and follow-up angiographic restenosis.
RESULTS Patients with intermediate lesions randomized to DES versus BMS had low rates of 30-day
MACE (1.1% vs. 4.0% respectively; p  0.22). At one-year follow-up, patients treated with
DES versus BMS had similar rates of cardiac death (0% vs. 2.7%, respectively; p  0.11) and
MI (3.4% vs. 5.4%; p 0.49) but markedly lower rates of TVR (3.4% vs. 20.3%; p 0.0004),
MACE (5.6% vs. 25.4%; p  0.0003), and binary angiographic restenosis (1.8% vs. 34.0%;
p  0.0001). No patient in either group developed stent thrombosis.
CONCLUSIONS Compared with BMS, treatment of intermediate lesions with DES appears safe and results
in a marked reduction in clinical and angiographic restenosis. The efficacy of DES may
require a reevaluation of current treatment paradigms for intermediate lesions. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.068Cardiol 2006;47:2164–71) © 2006 by the American College of Cardiology Foundation
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Intermediate coronary lesions are frequently found on diag-
ostic coronary angiography. The decision whether to treat
uch lesions continues to be a challenge. In the presence of
ypical angina and evidence of ischemia on the noninvasive
esting, revascularization is usually warranted (1). If the
esults of noninvasive testing are not available, inconclusive,
r contradictory, or if more than one intermediate lesion is
resent in the same vessel, adjunctive diagnostic modalities
o guide management are recommended (2–6). Such mo-
alities include assessment of the physiologic significance of
he lesion using pressure-derived myocardial fractional flow
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Manuscript received September 19, 2005; revised manuscript received December
3, 2005, accepted January 9, 2006.eserve (FFR) or the evaluation of the luminal dimensions
nd morphology of the atherosclerotic plaque and vascular
all using intravascular ultrasound (IVUS) (2–6). In several
tudies, deferring of coronary intervention for intermediate
tenosis with normal physiology (FFR 0.75) was consis-
ently associated with relatively low (6.3% to 11%) rates of
ajor adverse cardiac events (MACE) during follow-up
anging from six months to three years (7–10). Likewise,
edically treated patients with minimal luminal area 4.0
m2 by IVUS had only an 8% rate of cardiac events at mean
ollow-up of 13 months (11). In general, deferred interven-
ion based on these criteria has been associated with fewer
linical events than a deliberate interventional strategy
7,9,10).
Introduction of drug-eluting stents (DES) into clinical
ractice may potentially challenge this paradigm for the
anagement of intermediate lesions. However, scant data
ave been reported on the safety and efficacy of DES in the
reatment of patients with intermediate coronary lesions.
n a small series of 20 consecutive patients with 23 angio-
raphically mild (50% by quantitative coronary angiog-
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June 6, 2006:2164–71 Intermediate Lesions Treated With DESaphy [QCA]), de novo lesions from the Rapamycin-
luting Stent Evaluated At Rotterdam Cardiology Hospital
RESEARCH] registry treated with sirolimus-eluting
tents, survival free of MACE was 95% at a mean follow-up
f 399 days with no cases of target lesion revascularization
12). To further address the question of safety and efficacy of
ES in the treatment of intermediate lesions, we performed
patient-level pooled analysis of four randomized DES
ersus bare-metal stent (BMS) trials and assessed the
utcomes among patients undergoing percutaneous coro-
ary intervention (PCI) for intermediate lesions.
ETHODS
atient population. This study represents a retrospective
nalysis of patients with intermediate target lesions (50%
iameter stenosis as defined by QCA) from four random-
zed DES versus BMS clinical trials. The choice of trials
as based on the similarity of clinical and angiographic
haracteristics for the entry into the trial. The individual
ata of patients from the following four prospective, ran-
omized, and controlled trials were pooled: Sirolimus-
oated Bx Velocity Balloon Expandable Stent in the
reatment of Patients With de Novo Coronary Artery
esions (SIRIUS), TAXUS-IV, and the first and second
irst Use to Underscore Restenosis Reduction With
verolimus (FUTURE-I and -II). Outcomes were assessed
n-hospital, at 30 days, and at 1 year.
The protocols and the principal results of SIRIUS,
AXUS-IV, FUTURE-I, and FUTURE-II trials have
een reported elsewhere (13–19). Briefly, in the SIRIUS
rial, 1,058 patients at 53 U.S. centers were randomized to
sirolimus-eluting or a bare-metal Bx Velocity stent (both
rom Cordis Corp., Warren, New Jersey) (13,14). The
AXUS-IV study was a randomized trial that compared
utcomes of 1,314 patients at 73 U.S. centers treated with
he slow-release, polymer-based, paclitaxel-eluting Taxus
tent or a bare-metal Express stent (both from Boston
cientific Corp., Natick, Massachusetts) (15,16). In the
UTURE-I trial, 42 nondiabetic patients at a single center
ere randomized in a 2:1 mode to either an everolimus-
luting Challenge EES stent or the bare-metal S-Stent
both from Biosensors International, Singapore) (17,18).
Abbreviations and Acronyms
BMS  bare-metal stent
DES  drug-eluting stent
FFR  fractional flow reserve
IVUS  intravascular ultrasound
MACE  major adverse cardiac events
MI  myocardial infarction
PCI  percutaneous coronary intervention
QCA  quantitative coronary angiography
TLR  target lesion revascularization
TVR  target vessel revascularizationubsequently, 64 patients at four centers were random- fzed 1:1 to the Challenge EES stent or the bare-metal
-Stent in the FUTURE-II trial (19).
Common to all four trials, patients with stable or unstable
ngina or inducible ischemia underwent stent-assisted PCI
or a single de novo lesion (stenosis of 51% to 99% of the
uminal diameter by visual assessment on baseline angiog-
aphy) in a native coronary artery coverable by a single study
tent. Target lesion length was 15 to 30 mm in the SIRIUS
rial, 10 to 28 mm in the TAXUS-IV trial, and 18 mm in
he FUTURE-I and -II trials. Diameters of study and
ontrol stents were 2.5, 3.0, and 3.5 mm in all of the trials,
nd stents 4.0 mm in diameter also were available in the
UTURE-I and -II studies. The recommended duration of
lopidogrel treatment post-PCI was six months in all the
rials with the exception of the SIRIUS trial that advocated
herapy with clopidogrel for three months. Primary end
oints differed across the trials: nine-month target vessel
ailure (cardiac death, myocardial infarction [MI], or target
essel revascularization [TVR]) in the SIRIUS trial; nine-
onth TVR in the TAXUS-IV trial; 30-day MACE,
ncluding death, target lesion revascularization (TLR), or
I in the FUTURE-I trial; and in-stent late loss in the
UTURE-II trial. By study protocol, angiographic
ollow-up was performed at eight months in SIRIUS, nine
onths in the TAXUS-IV trial, and six months in the
UTURE-I and -II trials.
efinitions and clinical end points. In all trials the
efinition of MI was creatinine kinase greater than twice the
pper limit of the normal range accompanied by an elevated
evel of creatine kinase-MB in the absence or presence of
ew pathologic Q waves on the electrocardiogram (for
on–Q- or Q-wave MI, respectively). The definition of
LR was also identical across trials: any repeat percutaneous
ntervention of the target lesion or bypass surgery of the
arget vessel performed for recurrent angina, ischemia, or
CA diameter stenosis 70%. Target vessel revasculariza-
ion was defined as any clinically driven repeat PCI of the
arget vessel or bypass surgery of the target vessel. In each
rial, all clinical end points were adjudicated by an indepen-
ent clinical events committee blinded to the treatment
ssignment.
uantitative coronary angiography. Quantitative angio-
raphic measurements were performed by an independent
ngiographic core laboratory which was blinded to the
reatment assignment: the Brigham and Women’s Angio-
raphic Core Laboratory, Boston, Massachusetts, for the
IRIUS and TAXUS-IV trials and the Angiographic Core
aboratory of the Cardiovascular Research Foundation,
ew York, New York, for the FUTURE-I and -II trials.
easurements included the stented segment (in-stent) as
ell as the lesion segment (the stented segment plus
argins 5 mm proximal and distal to the stent [analysis
egment]). For the purposes of the present report, an
ntermediate lesion was defined by baseline QCA as 50%
iameter stenosis. Binary restenosis at angiographic
ollow-up was defined as diameter stenosis 50%.
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Intermediate Lesions Treated With DES June 6, 2006:2164–71tatistical analysis. Continuous variables are expressed as
ean  1 standard deviation and compared by unpaired
tudent t test. Categoric data are presented as frequencies
nd percentages and are compared using the Fisher exact
est. Out-of-hospital outcomes were estimated by the
aplan-Meier method and compared using log rank tests.
djusted event rates were determined using a multivariate
ox proportional hazards model to control for significant (p
0.05) baseline covariates. All tests were two sided with a
ignificance level of 0.05. Heterogeneity of the treatment
ffect on major outcomes across the trials was tested using a
ox proportional hazards model with a study  treatment
nteraction term included, also controlling for baseline
atient characteristics. The significance of interaction was
valuated using the likelihood ratio test.
ESULTS
aseline clinical and angiographic characteristics. Of the
,478 lesions randomized to DES versus BMS in the four
rials, 167 lesions (6.7%) were of intermediate severity,
ncluding 101 of 1,058 (9.5%) in the SIRIUS trial, 52 of
,314 (3.9%) in the TAXUS-IV trial, and 14 of 106 (13.2%)
n the FUTURE-I and -II trials. A total of 92 lesions were
reated with a DES (57 in the SIRIUS trial, 29 in the
AXUS-IV trial, and 6 in the FUTURE-I and -II trials),
nd 75 lesions with a BMS (44, 23, and 8, respectively).
Baseline clinical and angiographic data of patients from
he pooled analysis assigned to DES versus BMS are
resented in Table 1. Patients treated with DES compared
o those treated with BMS tended to be older, had a higher
able 1. Baseline Clinical Characteristics and Angiographic
eatures
DES
(n  92)
BMS
(n  75) p
linical characteristics
Age (yrs) 64.2  11.9 60.8  11.7 0.06
Male gender (%) 70.7 65.3 0.51
Diabetes mellitus (%) 21.7 27.0 0.47
Hypertension (%) 70.7 73.0 0.86
Hyperlipidemia (%) 74.2 69.3 0.60
Current smoking (%) 18.0 24.7 0.33
Prior myocardial infarction (%) 25.3 22.7 0.72
Prior PCI (%) 38.0 21.3 0.03
Prior coronary bypass surgery (%) 12.0 4.0 0.09
Unstable angina (%) 42.4 28.0 0.07
ngiographic features
Lesion length (mm) 11.4  4.83 11.2  4.44 0.76
Reference vessel diameter (mm) 2.85  0.46 2.86  0.51 0.86
Minimal luminal diameter (mm) 1.59  0.31 1.63  0.35 0.42
Diameter stenosis (%) 44.3  5.3 43.1  6.4 0.21
Target artery (%)
Left anterior descending artery 50.0% 58.7% 0.28
Left circumflex artery 19.6% 18.7% 1.00
Right coronary artery 29.3% 22.7% 0.37
TIMI flow grade 3 (%) 98.9% 100.0% 1.0
Left ventricle ejection fraction (%) 56.8  9.8 58.6  10.9 0.24w
MS  bare-metal stent; DES  drug-eluting stent; PCI  percutaneous coronary
ntervention; TIMI  Thrombolysis In Myocardial Infarction.requency of unstable angina at clinical presentation, and
ere more frequently treated with PCI in the past. Other
haracteristics were closely matched between the groups.
aseline and post-procedure angiographic measures and
rocedure characteristics also did not differ significantly
etween the patients treated with DES and BMS (Tables 1
nd 2). Pre-procedure target lesion diameter stenosis ranged
rom 24.6% to 49.9% in the DES group and from 25.5% to
9.9% in the BMS group.
n-hospital and 30-day outcomes. In-hospital MACE
ccurred rarely and with similar frequency in both groups
Table 3). The only in-hospital event in patients treated
ith DES was one case of a non–Q-wave MI (in the
IRIUS trial). In patients treated with BMS, there were two
ases of non–Q-wave MI (2.7%) (one patient in the SIRIUS
rial and one in the TAXUS trial).
At 30-day follow-up, no additional MACE occurred in
atients treated with DES whereas there was one more
on–Q-wave MI in patients treated with BMS (in the
IRIUS trial). As a result, 30-day MACE rates were 1.1%
ersus 4.0%, respectively (p  0.22). There were no early
tent thromboses in either group.
When stratified by the stent type and peri-procedure
dministration of platelet glycoprotein IIb/IIIa inhibitors
Table 4), outcomes were not related to the treatment with
lycoprotein IIb/IIIa inhibitors in patients that underwent
mplantation of DES (at 30 days, 0% vs. 2.2% patients that
ere treated with glycoprotein IIb/IIIa inhibitors vs. those
ho had not experienced MI or MACE; p 0.32), whereas
n patients that underwent implantation of BMS there was
trend toward decreased incidence of 30-day MI and
ACE in patients treated versus not treated with glyco-
rotein IIb/IIIa inhibitors (0% vs. 6.8%, respectively; p 
.14). Notably, at 30 days, patients treated with glyco-
rotein IIb/IIIa inhibitors in both DES and BMS groups
able 2. Procedure Results
DES
(n  92)
BMS
(n  75) p
inal reference-vessel
diameter (mm)
2.89  0.43 2.89  0.49 0.91
inal minimal luminal
diameter (mm)
Analysis segment 2.43  0.46 2.45  0.47 0.81
In-stent 2.78  0.44 2.76  0.41 0.74
inal diameter stenosis (%)
Analysis segment 15.87  7.75 18.85  10.4 0.92
In-stent 3.51  8.99 2.82  11.05 0.73
cute gain (mm)
Analysis segment 0.85  0.27 0.83  0.30 0.71
In-stent 1.19  0.31 1.14  0.27 0.22
IMI flow grade 3 (%) 100.0% 100.0% —
se of IIb/IIIa receptor
inhibitors (%)
50.0% 41.3% 0.28
rocedure success (%) 98.8% 97.0% 0.58
bbreviations as in Table 1.ere completely free from cardiac events.
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June 6, 2006:2164–71 Intermediate Lesions Treated With DESne-year outcomes. One-year clinical follow-up was
vailable in all patients (Table 3). In patients treated with
ES, there were no cardiac deaths, two additional non–Q-
ave MIs (in the SIRIUS trial), one TLR (in the SIRIUS
rial), and three TVRs (two in the SIRIUS trial and one in
he TAXUS-IV trial). Among patients treated with BMS,
here were two cardiac deaths (in the SIRIUS trial), one
dditional non–Q-wave MI (in the SIRIUS trial), and 15
ecurrences requiring either TLR or TVR (11 in the
IRIUS trial, 3 in the TAXUS-IV, and 1 in the
UTURE-I and -II trials). As a result, treatment with
MS rather than DES was associated with significantly
igher rates of one-year TLR (20.3% [95% confidence
Table 3. Clinical Outcomes
In-hospital
Cardiac death, n (%)
Myocardial infarction, n (%)
Target vessel revascularization, n (%)
Composite adverse cardiac events, n (%)*
30-day (cumulative)
Cardiac death, n (%)
Myocardial infarction, n (%)
Target vessel revascularization, n (%)
Composite adverse cardiac events, n (%)*
1-yr (cumulative)
Cardiac death, n (%)
Myocardial infarction, n (%)
Q-wave
Non–Q-wave
Stent thrombosis, n (%)
Target lesion revascularization, n (%)
Target vessel revascularization, n (%)
Composite adverse cardiac events, n (%)*
*Defined as the composite occurrence of either cardiac dea
ischemia.
Abbreviations as in Table 1.
able 4. Clinical Outcomes Stratified by Stent Type and Peri-Pr
Outcomes
D
() IIb/IIIa
n  46
(
n-hospital
Cardiac death, n (%) 0 (0)
MI, n (%) 0 (0)
TVR, n (%) 0 (0)
Composite adverse cardiac events, n (%)* 0 (0)
0-day (cumulative)
Cardiac death, n (%) 0 (0)
MI, n (%) 0 (0)
TVR, n (%) 0 (0)
Composite adverse cardiac events, n (%)* 0 (0)
-yr (cumulative)
Cardiac death, n (%) 0 (0)
MI, n (%) 1 (2.2%)
TLR, n (%) 1 (2.2%)
TVR, n (%) 1 (2.2%)
Composite adverse cardiac events, n (%)* 1 (2.2%)Defined as the composite occurrence of either cardiac death or myocardial infarction or ta
MI  myocardial infarction; TLR  target lesion revascularization; TVR  target vesnterval (CI) 9.4% to 31.1%] vs. 1.2% [95% CI 0% to
.0%]), TVR (20.3% [95% CI 9.4% to 31.1%] vs. 3.4%
95% CI 0% to 7.7%]), and MACE (25.4% [95% CI 13.6%
o 37.3%] vs. 5.6% [95% CI 0.1% to 11.1%]) and with lower
vent-free survival (Fig. 1). After controlling for significant
aseline covariates, patients treated with DES compared
ith patients treated with BMS still had significantly lower
ne-year TLR (1.2% vs. 20.3%; p  0.0001), TVR (3.2 vs.
9.2%; p 0.004), and composite MACE (4.1% vs. 23.5%;
 0.001). Of note, no patient in either group developed
tent thrombosis through one-year follow-up.
Testing for the heterogeneity of the treatment effect using
ultivariate models with and without study  treatment
(n  92) BMS (n  75) p
(0) 0 (0) —
(1.1%) 2 (2.7%) 0.58
(0) 0 (0) —
(1.1%) 2 (2.7%) 0.58
(0) 0 (0) —
(1.1%) 3 (4.0%) 0.22
(0) 0 (0) —
(1.1%) 3 (4.0%) 0.22
(0) 2 (2.7) 0.11
(3.4) 4 (5.4) 0.49
(0) 0 (0) —
(3.4) 4 (5.4) 0.49
(0) 0 (0) —
(1.2) 15 (20.3) 0.0001
(3.4) 15 (20.3) 0.0004
(5.6) 19 (25.4) 0.0003
myocardial infarction or target vessel revascularization for
re Administration of Platelet Glycoprotein IIb/IIIa Inhibitors
BMS
b/IIIa
46 p
() IIb/IIIa
n  31
() IIb/IIIa
n  44 p
— 0 (0) 0 (0) —
2%) 1.0 0 (0) 2 (4.5%) 0.51
— 0 (0) 0 (0) —
2%) 1.0 0 (0) 2 (4.5%) 0.51
— 0 (0) 0 (0) —
2%) 0.32 0 (0) 3 (6.8%) 0.14
— 0 (0) 0 (0) —
2%) 0.32 0 (0) 3 (6.8%) 0.14
— 0 (0) 2 (4.7%) 0.23
3%) 0.52 0 (0) 4 (9.2%) 0.08
0.34 6 (19.4%) 9 (21.0%) 0.82
3%) 0.52 6 (19.4%) 9 (21.0%) 0.82
7%) 0.15 6 (19.4%) 13 (29.7%) 0.28DES
0
1
0
1
0
1
0
1
0
3
0
3
0
1
3
5
th orocedu
ES
) II
n 
0 (0)
1 (2.
0 (0)
1 (2.
0 (0)
1 (2.
0 (0)
1 (2.
0 (0)
2 (4.
0 (0)
2 (4.
4 (8.rget vessel revascularization for ischemia.
sel revascularization; other abbreviations as in Table 1.
i
c
s
0
T
s
A
a
5
(
m
w

w
3
P
m
l
a
D
T
c
d
o
6
r
b
s
D
3
y
m
m
o
F
E
d
6
d
Q
c
l
a
p
(
i
d
F ) of p
v get ve
T
R
M
D
L
B
A
2168 Moses et al. JACC Vol. 47, No. 11, 2006
Intermediate Lesions Treated With DES June 6, 2006:2164–71nteraction term and adjustment for significant baseline
haracteristics showed that the interaction term was not
ignificant from the likelihood ratio test (p  0.29 and p 
.99 for one-month and one-year MACE, respectively).
herefore, the treatment effect was homogeneous across
tudies.
ngiographic follow-up. Angiographic follow-up was
vailable in 57 of 92 patients (61.9%) treated with DES and
3 of 75 patients (70.6%) treated with BMS (p  0.19)
Table 5). In-stent segment binary restenosis rates were
arkedly reduced in patients treated with DES compared
ith patients receiving a BMS (1.8% vs. 32.1%; difference
30.3% [95% CI 49.3% to 12.8%]). The same was true
ith regard to rates of in-lesion binary restenosis (1.8% vs.
4.0%; difference 32.2% [95% CI 51.0% to 14.7%]).
atients randomized to a DES had a significantly larger
inimal luminal diameter, lower diameter stenosis, and
igure 1. One-year survival free from major adverse cardiac events (MACE
ersus bare-metal stents (BMS). MI  myocardial infarction; TVR  tar
able 5. Angiographic Follow-Up Findings
DES
(n  57)
BMS
(n  53) p
eference-vessel diameter (mm) 2.91  0.47 2.87  0.45 0.65
inimal luminal diameter (mm)
Analysis segment 2.38  0.54 1.81  0.75 0.0001
In-stent 2.68  0.57 1.96  0.86 0.0001
iameter stenosis (%)
Analysis segment 18.4  11.1 37.9  21.5 0.0001
In-stent 7.4  14.2 33.2  24.8 0.0001
ate loss (mm)
Analysis segment 0.15  0.34 0.68  0.71 0.0001
In-stent 0.15  0.38 0.86  0.71 0.0001
inary restenosis rate (%)
Analysis segment 1.8% 34.0% 0.0001
In-stent 1.8% 32.1% 0.0001sbbreviations as in Table 1.ess late loss at follow-up than patients assigned to receive
BMS.
ISCUSSION
he principal findings of this pooled analysis of the out-
omes of patients with intermediate coronary lesions ran-
omized to DES versus BMS are as follows. 1) Due to
verestimation of the stenosis severity by visual assessment,
.7% (95% CI 3.9% to 13.2%) of patients in the analyzed
andomized trials had lesions with diameter stenosis 50%
y QCA, generally considered as mild or intermediate in
everity. 2) The treatment of intermediate lesions with
ES was safe, with very low rates of in-hospital and
0-day complications, and no stent thromboses at one
ear. 3) When compared with BMS, DES resulted in a
arked reduction in restenosis and, consequently, dra-
atically lower rates of TLR, TVR, and MACE at
ne-year follow-up.
requency and definition of an intermediate lesion.
ach of the four trials’ inclusion criteria required a lesion
iameter stenosis 50% by visual assessment. However,
.7% of the patients in this pooled analysis had lesion
iameter stenosis 50% when assessed objectively using
CA (mean stenosis severity 44%). This incidence is
omparable to the data on the incidence of intermediate
esions (using the same definition) reported from a pooled
nalysis from 14 randomized studies and registries of
atients treated with balloon angioplasty (8.3%) or BMS
4.1%) (20).
Of note, there is no consensus regarding the definition of
ntermediate lesion in the literature. The “visual estimation”
efinition of an intermediate lesion was 30% to 70% in
atients with intermediate lesions randomized to drug-eluting stents (DES)
ssel revascularization.tudies by Miller et al. (21) and Meuwissen et al. (22), 40%
t
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June 6, 2006:2164–71 Intermediate Lesions Treated With DESo 70% in studies by Bech et al. (23) and Chamuleau et al.
8), 50% in a study by Pijls et al. (4), and 70% in a study
y Abizaid et al. (11). Even so, the 44% mean diameter
tenosis at the site of intermediate lesions as measured by
CA was similar in this analysis to the other studies on
ntermediate lesions reporting QCA data (4,11,22,23).
Given the cost of DES, more precise assessment of
ntermediate lesions such as online QCA, IVUS, or invasive
hysiology is warranted.
reatment of intermediate lesions with BMS. In this
urrent pooled analysis, treatment of intermediate lesions
ith BMS was associated with a 25.4% rate of MACE at
ne-year follow-up, similar to that reported from the pooled
nalysis of 14 randomized studies and registries using stents
f earlier design (22%) (20). In both pooled analyses the
ajority of MACE was attributed to TLR and TVR (20.3%
nd 18.7%, respectively). Furthermore, the 25.4% one-year
ACE rate with BMS in the current report was substan-
ially higher than both the 11.1% and 17.8% two-year rates
bserved with the deferred PCI strategies in intermediate
esions with FFR 0.75 and similar to the 29.2% two-year
ACE rate with PCI in intermediate lesions with FFR
0.75 in the Deferral Versus Performance of Percutaneous
ransluminal Coronary Angioplasty in Patients Without
ocumented Ischemia trial (7). These findings extend even
o lesions with diameter stenosis 50%. Collectively, these
ata suggest that BMS should not routinely be used to treat
ntermediate lesions without further physiologic or ana-
omic delineation.
reatment of intermediate lesions with DES. In con-
rast, patients in the present analysis in whom intermediate
esions were treated with DES had very low rates of early
nd late clinical events. No patient died or developed
-wave MI or stent thrombosis. Rates of non–Q-wave MI
ere low (3.4% [95% CI 0% to 7.1%]) and not unquestion-
igure 2. Rates of major adverse cardiac events (MACE) in patients wit
hysiologic lesion assessment (fractional flow reserve 0.75) or intravascular ult
urrent pooled analysis of drug-eluting stent (DES)-treated patients from fourbly were attributed to the target lesion or vessel. A
emarkably low rate of angiographic restenosis (1.8% [95%
I 0.1% to 8.9%]) was observed in intermediate lesions
reated with DES at follow-up angiography. As a result,
nly one patient (1.2%) required TLR at one-year after
ES implantation in an intermediate lesion. Although
either IVUS nor physiologic testing of the intermediate
esions in these trials was performed to determine which
ere ischemia producing or anatomically significant, the
ne-year observed MACE rate of 5.6% compares favorably
ith historical control MACE rates from studies in which
CI was deferred based on these tests (Fig. 2) (7–11,23).
he safety of treating intermediate lesions with DES
xtends even to lesions with diameter stenosis 50%.
Remarkable also is the absence of 30-day events in
atients treated with platelet glycoprotein IIb/IIIa inhibi-
ors. Assuming this therapy has been given to the high-risk
atients with unstable angina or unfavorable angiographic
haracteristics (e.g., ulcerated plaque or thrombus-
ontaining lesion), the low event rate in this cohort is of
articular importance.
otential clinical implications. The highly favorable out-
omes in patients with intermediate coronary lesions treated
ith DES in the present study should not be interpreted as
current call to liberalize the well-accepted criteria for
ntervention in lesions likely to be of hemodynamic signif-
cance. However, given the low risk of adverse events and
estenosis with DES in this study, the results of the present
tudy may impact trial design investigating future strategies
o prevent plaque rupture and progression of atherosclerosis.
Though prospective randomized trials will be required to
alidate the safety, efficacy, and cost effectiveness of prophy-
actic DES implantation, baseline elevation of inflammatory
arkers may help identify which intermediate lesions may
e at imminent risk for progression. Meuwissen et al. (22)
rmediate lesions in studies in which intervention was deferred based on
2h inte
rasound analysis (minimal cross-sectional area 4.0 mm ) (7–11) vs. the
randomized trials.
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Intermediate Lesions Treated With DES June 6, 2006:2164–71tudied 71 patients with intermediate lesions in which PCI
as deferred based on FFR 0.75. In 8% of patients TLR
as required at a mean follow-up of 318 days. Among the
ubset of patients with an elevated C-reactive protein (5.0
g/l), the TLR rate was 27.8%, with most events occurring
ithin six months. In patients requiring TLR, the mean
iameter stenosis increased from 46.1% at baseline to 62.0%
t follow-up (22).
Important data have also recently emerged describing a
onuniform spatial distribution of coronary thrombosis
esulting in ST-segment elevation MI, with propensity for
laque rupture in the proximal segments of coronary arteries
24). Intermediate lesions located in these zones might
epresent a potential substrate for preventive intervention
sing DES. Thus, mounting evidence supports the necessity
or sophisticated focal and regional approaches to identify
egments of the coronary tree vulnerable to plaque progres-
ion and rupture. The present study suggests that DES
mplantation may possess the requisite safety and efficacy
rofile to consider plaque stabilization in such coronary
egments. No doubt, the risk of late stent thrombosis and
he requirement in extended combined antithrombotic ther-
py including aspirin and thienopyridine after DES implan-
ation should be carefully weighed in deciding to use DES
o treat an intermediate lesion.
tudy limitations. The present post hoc analysis was not
respecified, and should therefore be considered as hypoth-
sis generating. Inherently to all pooled analyses, the four
rials differed somewhat in design, inclusion/exclusion cri-
eria, stent design, and antiproliferative agents. Two differ-
nt laboratories performed the QCA analyses. Nonetheless,
he majority of baseline clinical and angiographic character-
stics of the patients from the four trials were similar, and
here was no evidence of statistical heterogeneity of the
reatment effect in outcomes across the studies after adjust-
ent for baseline clinical and angiographic characteristics.
he study sample of 167 patients is modest, with even fewer
atients undergoing angiographic follow-up; larger studies
ould be required to narrow the efficacy point estimates and
o define if the usage of platelet glycoprotein IIb/IIIa
nhibitors may further reduce ischemic clinical events in
atients with intermediate lesions. However, it is unlikely
hat future randomized trials of DES versus BMS in
ntermediate lesions will be performed. Angiographic
ollow-up was available for only 65.9% of the patients;
herefore, the precise rates of restenosis may differ from
hose reported in this study. Information on inducible
schemia, physiologic lesion assessment, and inflammatory
iomarkers was not available in these studies; it would have
een useful to further characterize the patients and lesions.
inally, the operators believed the treated lesions to be of
ufficient clinical relevance to require treatment. Therefore,
he results of this analysis cannot directly be extrapolated to
esions of lesser severity or to lesions requiring greater stent
ength. Moreover, it is unknown what percentage of the
esions treated in the present study were thin-capped fibro-theromas, and as such further studies are required to
emonstrate the safety and efficacy of DES implantation in
ruly vulnerable plaques.
onclusions. The current study suggests that the use of
ES to treat intermediate lesions is safe and is associated
ith very low rates of early and one-year MACE. Prospec-
ive studies are therefore warranted to examine the benefits
f DES compared to deferred intervention and maximal
edical therapy in patients with intermediate stenoses of
orderline hemodynamic significance, which may be prone
o symptomatic progression, and in potentially vulnerable
theroma prone to plaque rupture resulting in acute coro-
ary syndromes or sudden death.
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